Estrogen receptors

new perspectives in breast cancer management

E. Petrangeli, C. Lubrano, F. Ortolani, L. Ravenna, A. Vacca, S. Sciacchitano, L. Frati, A. Gulino, A. Vacca, S. Sciacchitano, L. Frati, A. Gulino

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The imbalance between proliferative and differentiative estrogenic effect, caused by quantitative and qualitative alteration of the estrogen receptor (ER) expression, may play a determinant role in mammary neoplastic transformation. Our studies demonstrate that ER levels are significantly higher in human mammary neoplastic tissues when compared to perineoplastic tissues and that increased ER expression is associated with ER gene hypomethylation. During progressive multifactorial carcinogene, ER overexpression may represent an early step in neoplastic transformation. In fact, high levels of ER represent good markers of differentiation and can predict the likelihood of benefiting from anti-estrogen therapy. Nevertheless, about 35% of ER-positive breast cancers are resistant to endocrine therapy and 10% of ER-negative tumors behave as hormone-sensitive tumors. Recent studies on ER mRNA variants, which naturally occur in human breast tumors, demonstrated mutations, deletions and alternative splicings, yielding deletions of exons 3, 4, 5 and 7. ER variants exhibited altered functions or changed the responsiveness to hormonal therapy. Analysis of these variants could be a useful parameter to better predict tumor responsiveness to anti-estrogen therapy. Recently, a regain of hormonal responsiveness by ER-negative breast cancer cells has been reported following ER gene transfection. However, estradiol treatment inhibits rather than stimulates cell growth as well as the metastatic and invasive potential of the ER gene transduced cells. Transfer of the ER gene may be considered as a new therapeutic approach in the management of hormone-independent breast cancer.

Original languageEnglish
Pages (from-to)327-331
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume49
Issue number4-6
DOIs
Publication statusPublished - 1994

Fingerprint

Estrogen Receptors
Breast Neoplasms
Tumors
Genes
Estrogens
Breast
Hormones
Tissue
Therapeutics
Neoplasms
Regain
Sequence Deletion
Differentiation Antigens
Alternative Splicing
Cell growth
Transfection
Estradiol
Exons
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Petrangeli, E., Lubrano, C., Ortolani, F., Ravenna, L., Vacca, A., Sciacchitano, S., ... Gulino, A. (1994). Estrogen receptors: new perspectives in breast cancer management. Journal of Steroid Biochemistry and Molecular Biology, 49(4-6), 327-331. https://doi.org/10.1016/0960-0760(94)90275-5

Estrogen receptors : new perspectives in breast cancer management. / Petrangeli, E.; Lubrano, C.; Ortolani, F.; Ravenna, L.; Vacca, A.; Sciacchitano, S.; Frati, L.; Gulino, A.; Vacca, A.; Sciacchitano, S.; Frati, L.; Gulino, A.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 49, No. 4-6, 1994, p. 327-331.

Research output: Contribution to journalArticle

Petrangeli, E, Lubrano, C, Ortolani, F, Ravenna, L, Vacca, A, Sciacchitano, S, Frati, L, Gulino, A, Vacca, A, Sciacchitano, S, Frati, L & Gulino, A 1994, 'Estrogen receptors: new perspectives in breast cancer management', Journal of Steroid Biochemistry and Molecular Biology, vol. 49, no. 4-6, pp. 327-331. https://doi.org/10.1016/0960-0760(94)90275-5
Petrangeli, E. ; Lubrano, C. ; Ortolani, F. ; Ravenna, L. ; Vacca, A. ; Sciacchitano, S. ; Frati, L. ; Gulino, A. ; Vacca, A. ; Sciacchitano, S. ; Frati, L. ; Gulino, A. / Estrogen receptors : new perspectives in breast cancer management. In: Journal of Steroid Biochemistry and Molecular Biology. 1994 ; Vol. 49, No. 4-6. pp. 327-331.
@article{604c2732699a4b9b9ad11236ecd3256b,
title = "Estrogen receptors: new perspectives in breast cancer management",
abstract = "The imbalance between proliferative and differentiative estrogenic effect, caused by quantitative and qualitative alteration of the estrogen receptor (ER) expression, may play a determinant role in mammary neoplastic transformation. Our studies demonstrate that ER levels are significantly higher in human mammary neoplastic tissues when compared to perineoplastic tissues and that increased ER expression is associated with ER gene hypomethylation. During progressive multifactorial carcinogene, ER overexpression may represent an early step in neoplastic transformation. In fact, high levels of ER represent good markers of differentiation and can predict the likelihood of benefiting from anti-estrogen therapy. Nevertheless, about 35{\%} of ER-positive breast cancers are resistant to endocrine therapy and 10{\%} of ER-negative tumors behave as hormone-sensitive tumors. Recent studies on ER mRNA variants, which naturally occur in human breast tumors, demonstrated mutations, deletions and alternative splicings, yielding deletions of exons 3, 4, 5 and 7. ER variants exhibited altered functions or changed the responsiveness to hormonal therapy. Analysis of these variants could be a useful parameter to better predict tumor responsiveness to anti-estrogen therapy. Recently, a regain of hormonal responsiveness by ER-negative breast cancer cells has been reported following ER gene transfection. However, estradiol treatment inhibits rather than stimulates cell growth as well as the metastatic and invasive potential of the ER gene transduced cells. Transfer of the ER gene may be considered as a new therapeutic approach in the management of hormone-independent breast cancer.",
author = "E. Petrangeli and C. Lubrano and F. Ortolani and L. Ravenna and A. Vacca and S. Sciacchitano and L. Frati and A. Gulino and A. Vacca and S. Sciacchitano and L. Frati and A. Gulino",
year = "1994",
doi = "10.1016/0960-0760(94)90275-5",
language = "English",
volume = "49",
pages = "327--331",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "4-6",

}

TY - JOUR

T1 - Estrogen receptors

T2 - new perspectives in breast cancer management

AU - Petrangeli, E.

AU - Lubrano, C.

AU - Ortolani, F.

AU - Ravenna, L.

AU - Vacca, A.

AU - Sciacchitano, S.

AU - Frati, L.

AU - Gulino, A.

AU - Vacca, A.

AU - Sciacchitano, S.

AU - Frati, L.

AU - Gulino, A.

PY - 1994

Y1 - 1994

N2 - The imbalance between proliferative and differentiative estrogenic effect, caused by quantitative and qualitative alteration of the estrogen receptor (ER) expression, may play a determinant role in mammary neoplastic transformation. Our studies demonstrate that ER levels are significantly higher in human mammary neoplastic tissues when compared to perineoplastic tissues and that increased ER expression is associated with ER gene hypomethylation. During progressive multifactorial carcinogene, ER overexpression may represent an early step in neoplastic transformation. In fact, high levels of ER represent good markers of differentiation and can predict the likelihood of benefiting from anti-estrogen therapy. Nevertheless, about 35% of ER-positive breast cancers are resistant to endocrine therapy and 10% of ER-negative tumors behave as hormone-sensitive tumors. Recent studies on ER mRNA variants, which naturally occur in human breast tumors, demonstrated mutations, deletions and alternative splicings, yielding deletions of exons 3, 4, 5 and 7. ER variants exhibited altered functions or changed the responsiveness to hormonal therapy. Analysis of these variants could be a useful parameter to better predict tumor responsiveness to anti-estrogen therapy. Recently, a regain of hormonal responsiveness by ER-negative breast cancer cells has been reported following ER gene transfection. However, estradiol treatment inhibits rather than stimulates cell growth as well as the metastatic and invasive potential of the ER gene transduced cells. Transfer of the ER gene may be considered as a new therapeutic approach in the management of hormone-independent breast cancer.

AB - The imbalance between proliferative and differentiative estrogenic effect, caused by quantitative and qualitative alteration of the estrogen receptor (ER) expression, may play a determinant role in mammary neoplastic transformation. Our studies demonstrate that ER levels are significantly higher in human mammary neoplastic tissues when compared to perineoplastic tissues and that increased ER expression is associated with ER gene hypomethylation. During progressive multifactorial carcinogene, ER overexpression may represent an early step in neoplastic transformation. In fact, high levels of ER represent good markers of differentiation and can predict the likelihood of benefiting from anti-estrogen therapy. Nevertheless, about 35% of ER-positive breast cancers are resistant to endocrine therapy and 10% of ER-negative tumors behave as hormone-sensitive tumors. Recent studies on ER mRNA variants, which naturally occur in human breast tumors, demonstrated mutations, deletions and alternative splicings, yielding deletions of exons 3, 4, 5 and 7. ER variants exhibited altered functions or changed the responsiveness to hormonal therapy. Analysis of these variants could be a useful parameter to better predict tumor responsiveness to anti-estrogen therapy. Recently, a regain of hormonal responsiveness by ER-negative breast cancer cells has been reported following ER gene transfection. However, estradiol treatment inhibits rather than stimulates cell growth as well as the metastatic and invasive potential of the ER gene transduced cells. Transfer of the ER gene may be considered as a new therapeutic approach in the management of hormone-independent breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027983828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027983828&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(94)90275-5

DO - 10.1016/0960-0760(94)90275-5

M3 - Article

VL - 49

SP - 327

EP - 331

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 4-6

ER -